Search
News
ECDC and EMA collaborate on vaccine safety and effectiveness monitoring studies
The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) convened on 6 and 7 December in Amsterdam the first meeting of the Immunisation and Vaccine Monitoring Advisory Board (IVMAB) of the Vaccine Monitoring Platform (VMP).
Efficacy, effectiveness and safety of vaccines against COVID-19
This page gives an overview on the evidence by specific vaccine product, age groups and SARS-CoV-2 variants.
Scientific and technical publications
Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making
This technical report provides a summary of the evidence available at the time of the publication and what will be required in the future to support EU/EEA countries taking decisions on administration of the second dose, following a first dose of Vaxzevria. Since new evidence is being generated continuously and safety monitored on an ongoing basis, it is essential for readers to consider the latest available information.
COVID-19 vaccination
COVID-19 vaccines aim to prevent COVID-19 by triggering an immune response. Safe and effective COVID-19 vaccines are a powerful tool for controlling the pandemic.
Multimedia
Video on vaccination: Monitoring the safety of vaccines in Europe
Vaccines have been used to prevent diseases in millions of people worldwide. But who monitors the safety of vaccines and how do they do it?
Multimedia
Video on vaccination: How vaccines are approved in Europe
Only vaccines that are safe and effective are approved for use in the European Union. How does the process of vaccine authorisation look like? Watch our video (turn on subtitles in your language) to learn more!
Data
Evidence of the safety of the HPV vaccines in males
Efficacy/effectiveness, immunogenicity, safety and tolerability of the HPV vaccines in males
Data
Evidence of the safety of the 9vHPV vaccine
Efficacy/effectiveness, immunogenicity, safety and tolerability of the 9-valent HPV vaccine.
Data
Evidence of the safety of the HPV vaccine in HIV-infected men and women
Efficacy, immunogenicity, safety and tolerability in other populations not previously targeted by immunisation programmes: HIV-infected men and women
Scientific and technical publications
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines
Sturkenboom M, Bahri P, Chiucchiuini A, Grove Krause T, Hahné S, Khromava A, Kokki M, Kramarz P, Kurz X, Larson HJ, de Lusignan S, Mahy P, Torcel-Pagnon L, Titievsky L, Bauchau V; ADVANCE consortium..